HRID245725

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：Cc1nccn2c([C@@H]3CCN(CC(=O)N(C)C)C3)nc(Br)c12

HCID67364023

未命名化合物

结构：COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1NC(=O)c1cc2c(OC)cccc2n1C

HCID67365651

未命名化合物

PRODUCTS

生成物

结构：COc1cc(-c2nc([C@@H]3CCN(CC(=O)N(C)C)C3)n3ccnc(C)c23)ccc1NC(=O)c1cc2c(OC)cccc2n1C

HCID53344863

未命名化合物

收率 91.1%

PROCEDURE

实验过程

Reaction of (R)-2-(3-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)pyrrolidin-1-yl)-N,N-dimethylacetamide (22 mg) and 4-methoxy-N-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-methyl-1H-indole-2-carboxamide (23 mg) according to the procedure described in example 4 step 4c and purification using prep-HPLC (column Luna C18(2); gradient acetonitrile/water with constant 0.003M trifluoroacetic acid) gave (R)—N-(4-(3-(1-(2-(dimethylamino)-2-oxoethyl)pyrrolidin-3-yl)-8-methylimidazo[1,5-a]pyrazin-1-yl)-2-methoxyphenyl)-4-methoxy-1-methyl-1H-indole-2-carboxamide (28.6 mg).

WORKUP

后处理

customdescribed in example 4 step 4c and purification

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-0882485778f040ea85c74760fa8263d6
来源数据集: uspto-grants-2014_02
DOI: 10.6084/m9.figshare.5104873.v1
专利: US08658794B2
来源说明: uspto-grants-2014_02

反应 SMILES

Br[C:2]1[N:3]=[C:4]([C@@H:12]2[CH2:16][CH2:15][N:14]([CH2:17][C:18]([N:20]([CH3:22])[CH3:21])=[O:19])[CH2:13]2)[N:5]2[CH:10]=[CH:9][N:8]=[C:7]([CH3:11])[C:6]=12.[CH3:23][O:24][C:25]1[CH:33]=[CH:32][CH:31]=[C:30]2[C:26]=1[CH:27]=[C:28]([C:35]([NH:37][C:38]1[CH:43]=[CH:42][C:41](B3OC(C)(C)C(C)(C)O3)=[CH:40][C:39]=1[O:53][CH3:54])=[O:36])[N:29]2[CH3:34]>>[CH3:21][N:20]([CH3:22])[C:18](=[O:19])[CH2:17][N:14]1[CH2:15][CH2:16][C@@H:12]([C:4]2[N:5]3[CH:10]=[CH:9][N:8]=[C:7]([CH3:11])[C:6]3=[C:2]([C:41]3[CH:42]=[CH:43][C:38]([NH:37][C:35]([C:28]4[N:29]([CH3:34])[C:30]5[C:26]([CH:27]=4)=[C:25]([O:24][CH3:23])[CH:33]=[CH:32][CH:31]=5)=[O:36])=[C:39]([O:53][CH3:54])[CH:40]=3)[N:3]=2)[CH2:13]1